Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Pravachol investigation

Executive Summary

Bristol-Myers Squibb receives civil investigative demand from Missouri Attorney General relating to Pravachol DTC advertising from 2001-2003, 1Bristol's 10-K filing says. A separate, class action 2complaint filed in Kansas City, Mo. state court alleges the ads misled consumers "into purchasing Pravachol under the mistaken belief that it would help prevent strokes in people with high cholesterol even if they did not have any history of heart disease." In an August 2003 warning letter, FDA said the ads falsely implied that pravastatin is approved for prevention of stroke in patients without coronary heart disease (3"The Pink Sheet" Aug. 11, 2003, p. 4). Bristol issued a corrective ad in February. [Editor's note: For more coverage, log on to 4"The Pink Sheet" DAILY. Visit our website, www.ThePinkSheetDAILY.com to sign up for a free trial.]...

You may also be interested in...



Fujisawa Prograf Risk Education Plan Requested By FDA Warning Letter

Fujisawa will implement a Prograf risk education plan for physicians in response to FDA complaints that a journal ad for the organ rejection agent failed to present adequate risk information

Bristol Pravachol Ads Broaden Indication, FDA Warning Letter Says

FDA is asking Bristol-Myers Squibb to correct Pravachol advertising claims that the agency says broadens the indication and patient populations for which the cholesterol-lowering agent is approved

Bayer Execs On Digital Acceleration, Getting The Building Blocks Right

Senior executives from Bayer outlined at a recent summit the contours of digital transformation already underway and the vital components of a successful digital team. Firms need to be able to operate technology at the “speed of business” and not “at the speed of a ticketing queue.”

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel